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Abstract
Background Genomic information could help to reduce
the morbidity effects of inappropriate treatment decisions
in many disease areas, in particular cancer. However,
evidence of the benefits that patients derive from genomic
testing is limited. This study evaluated patient preferences
for genomic testing in the context of chronic lymphocytic
leukaemia (CLL).
Methods We used a discrete choice experiment (DCE)
survey to assess the preferences of CLL patients in the UK
for genomic testing. The survey presented patients with 16
questions in which they had to choose between two pos-
sible test scenarios. Tests in these scenarios were specified
in terms of six attributes, including test effectiveness, test
reliability and time to receive results.
Results 219 patients completed the survey (response rate
20 %). Both clinical and process-related attributes were
valued by respondents. Patients were willing to pay £24 for
a 1 % increase in chemotherapy non-responders identified,
and £27 to reduce time to receive test results by 1 day.
Patients were also willing to wait an extra 29 days for test
results if an additional one-third of chemotherapy non-
responders could be identified, and would tolerate a
genomic test being wrong 8 % of the time to receive this
information.
Conclusion CLL patients value the information that could
be provided by genomic tests, and prefer combinations of
test characteristics that more closely reflect future genomic
testing practice than current genetic testing practice.
Commissioners will need to carefully consider how geno-
mic testing is operationalised in this context if the benefits
of testing are to be realised.
Key Points for Decision Makers
Both clinical and process-related outcomes are
important to cancer patients when genomic tests are
used to guide chemotherapy treatment decisions.
Chronic lymphocytic leukaemia patients prefer
combinations of test characteristics that more closely
reflect future genomic testing practice than current
genetic testing practice.
1 Introduction
Genetic tests are diagnostic assays that are targeted to
specific genes of interest, or can identify large chromoso-
mal changes. These tests can inform disease diagnosis,
provide prognostic information and guide treatment deci-
sions, and are now established as routine practice in several
clinical areas, such as BRCA1/2 testing in breast cancer
[1]. In many of these clinical contexts attention is now
turning towards genomic interventions which could
Electronic supplementary material The online version of this
article (doi:10.1007/s40271-016-0172-1) contains supplementary
material, which is available to authorized users.
& James Buchanan
james.buchanan@dph.ox.ac.uk
1 Nuffield Department of Population Health, Health Economics
Research Centre, University of Oxford, Old Road Campus,
Headington, Oxford OX3 7LF, UK
2 BRC/NHS Oxford Molecular Diagnostics Centre, Oxford
University Hospitals NHS Foundation Trust, Oxford, UK
3 Department of Oncology, University of Oxford, Oxford, UK
Patient (2016) 9:525–536
DOI 10.1007/s40271-016-0172-1
improve disease stratification and permit the more wide-
spread use of individually tailored therapies. These next-
generation sequencing (NGS) technologies, which include
targeted-, whole-exome- and whole-genome sequencing,
offer genome-wide testing capability, simultaneously
scrutinising multiple genes and their inter-relationships in
order to identify their combined influence [2].
Although NGS technologies have shown promise in
allowing disease management to be stratified, they have
had a limited impact on clinical practice to date [3, 4]. In
part, this is because the evidence that usually informs
health technology assessment (HTA) processes around the
world is lacking in genomics. Evidence of the benefits that
patients derive from genomic testing is particularly limited.
Measuring these benefits is difficult because genomic tests
provide patients with both clinical utility (e.g. genetic
information can inform treatment decisions) and personal
utility (benefits or harms manifested outside medical con-
texts, e.g. ‘the value of knowing’) [5, 6]. Although these
informational and process-related benefits can be valued
more highly than clinical utility [7, 8], most HTA guide-
lines stipulate that cost-utility analyses should be con-
ducted using metrics such as the quality-adjusted life-year
(QALY). However, the estimation of QALYs is usually
informed by preference scores generated by instruments
which focus primarily on health outcomes (e.g. the EQ-5D
– a standardised measure of health-related quality of life),
rather than non-health outcomes. Ignoring these non-health
outcomes can in some cases change adoption decisions [9].
An alternative approach to using QALYs is to collect
information on patient preferences for genomic testing
using a quantitative technique called a discrete choice
experiment (DCE). Preferences are elicited in a DCE by
presenting respondents with a series of choices in which at
least two alternatives are specified in terms of their attri-
butes, which can vary across a finite number of levels.
Respondents complete these choice tasks in a survey and
econometric techniques are used to analyse their responses
and generate a model of choice behaviour. DCEs are now
commonly used to quantify patient preferences for com-
binations of intervention attributes (including both process-
and outcome-related characteristics) and provide informa-
tion on trade-offs between attributes, with recent applica-
tions including the assessment of genetic counselling and
genetic carrier testing [10]. The DCE approach may
therefore be well placed to fill some of the evidentiary gaps
in genomic HTAs by providing a more rounded summary
of the true benefits of testing for patients. Furthermore,
DCEs can also help to inform the design of services to
deliver genomic testing and education materials for
patients [11, 12].
This paper presents the results of a DCE which inves-
tigated the preferences of chronic lymphocytic leukaemia
(CLL) patients for genomic testing. CLL is the most
common adult leukaemia in the Western world [13], and
chemotherapy is usually offered to patients with symp-
tomatic disease. First-line treatment with fludarabine,
cyclophosphamide and rituximab (FCR) combination
therapy is the standard of care; however, 25 % of patients
will either fail to respond to FCR or will relapse within
2 years of achieving remission [14, 15]. Genetic factors
acquired during leukaemogenesis are thought to be the
main factors underlying treatment resistance, in particular
disruption of TP53, mutations in NOTCH1 (predictive of
non-response to Rituximab) and SF3B1, and global fea-
tures such as genomic complexity and clonal evolution [13,
16–22]. There is also increasing evidence that other genetic
abnormalities such as sole deletions of 13q are associated
with excellent long-term survival, meaning that chemo-
immunotherapy may even be curative [23]. Consequently,
current UK and international guidelines recommend that
patients undergo pre-treatment genetic testing to detect
TP53 disruption using fluorescent in situ hybridisation
testing and Sanger sequencing [24–26]. This low-resolu-
tion approach can identify a third of FCR non-responders,
but is unable to identify any of the other genetic abnor-
malities [27].
New genomic testing approaches such as targeted NGS
offer a whole genome view at increased resolution, pro-
viding additional information on multiple genetic alter-
ations with clinical utility (including several novel
mutations that can only be identified at high resolution),
and combinations of these alterations [15, 28, 29]. This
information could further reduce unnecessary treatment
and associated side effects [27, 30]. Genomic testing
approaches may therefore be able to identify the remaining
two-thirds of FCR non-responders, and may have addi-
tional process-related benefits (e.g. shorter time to receive
test result). However, these new testing approaches are yet
to be translated into clinical practice. While there is ample
evidence from randomised Phase III studies that this
extended genetic information is clinically useful [15–22,
28, 29], there is little information available on the costs and
benefits of extensive genetic testing in this context. Fur-
thermore, one possible consequence of a ‘non-response’
test result could be the use of expensive alternative thera-
pies such as ibrutinib. As such, it is important that decision-
makers are confident that the information provided by these
tests will truly be valued by patients.
The DCE presented in this paper aims to fill this evi-
dentiary gap by evaluating the preferences of CLL patients
for pre-treatment genetic and genomic testing. By captur-
ing information on both the clinical and personal utility of
testing to patients we provide decision-makers with a more
accurate illustration of the benefits of genomic testing in
CLL. In addition, we examine whether patient preferences
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vary by socio-demographic characteristics, by estimating a
basic multinomial logit choice model and then relaxing the
restricted assumptions underlying this model to account for
preference heterogeneity using more general models [31].
Finally, given that few studies have evaluated patient
preferences for genomic interventions in cancer [11], we
also provide clinicians and decision-makers with more
general information on which process and outcome-related
characteristics of genomic testing may be important to
other cancer patients.
2 Materials and Methods
This section describes the process of designing, adminis-
tering and analysing the DCE survey.
2.1 Selecting a Sampling Population
The sampling population selected for this DCE was UK
CLL patients as it is recommended that DCEs are under-
taken in populations with experience in the area of interest
[32]. To ensure that the sampling population reflected CLL
patients with a range of characteristics, two populations
were targeted. Population One included CLL patients
attending outpatient clinics in the Oxford University
Hospitals National Health Service Foundation Trust
(hereafter OUH) in the UK (n = 140), which is one of the
largest teaching trusts in the UK, providing acute care to a
population of 650,000 people. All CLL patients at OUH
requiring treatment can choose to participate in interven-
tional clinical trials of CLL treatments. Population Two
included all patient members of the UK CLL Support
Association (CLLSA, http://www.cllsupport.org.uk/;
n = 982), which is one of the largest patient-led charities
in the UK.
2.2 Establishing Attributes and Levels
Attributes and levels (the values that an attribute could
take) for the survey were developed using several
approaches. First, a literature search was conducted to
identify attributes used in previously published DCEs in
genetics or leukaemia. Three haematologists at OUH
reviewed these attributes, identifying nine that were
potentially relevant: those listed in Table 1, plus ‘Number
of blood samples required’, ‘Accuracy of the diagnosis’
and ‘Testing location’.
Interviews were then conducted by JB with 15 randomly
selected CLL patients at OUH, who were asked to rate how
important each attribute would be if they were deciding
whether to undergo pre-treatment testing. The six highest
ranked attributes were taken forward (Supplementary
Materials–Part One: Table S1), based on how many would
be manageable by this population, how many would be
required to enable informed choices, and which would best
capture the characteristics of current and future testing
practice. Four clinically-feasible levels were identified for
each attribute (informed by the interviews, literature sear-
ches and test characteristics). Potential interactions were
identified between the ability of the test to predict who will
respond to the usual chemotherapy treatment (EFFECT)
and COST, and also test reliability (REL) and COST (more
expensive tests may be perceived to be better quality).
Time to receive the test result (TIME), COST, EFFECT
and REL were assumed to be linear and coded as contin-
uous variables to facilitate the use of the DCE results in a
future cost-benefit analysis. Length of time clinicians spend
describing the test (INFO) and type of clinician who
explains the test result (WHO) were effects coded. This
decision was taken as the levels for these attributes may be
proxies for quantity or quality of information provided, so
the effect may not be linear. The use of effects coding
allows coefficients to be generated for each of the attribute
levels, which can then be analysed graphically to assess
whether a non-linear relationship exists. Table 1 also
describes the expected impact on patient utility of an
increase in the level of each attribute.
2.3 Experimental Design
The chosen attributes and levels were used to design a DCE
in which respondents were presented with choice sets
containing two alternatives (Test A vs. Test B). An alter-
native design including an opt-out was considered which
would have permitted the evaluation of potential test
uptake. To determine whether this would add additional
complexity to the experimental design for limited benefit, a
pilot DCE was generated with a two-stage design (Test A
vs. Test B, then Chosen test vs. No test). This was com-
pleted by a convenience sample of 14 members of the
University of Oxford, and six members of the general
public. ‘No test’ was selected in only 3.9 % of choices.
Given that genetic testing is currently recommended for
UK CLL patients [24] (hence their ability to choose ‘no
test’ is limited), and general population respondents may
consider an opt-out to be a more viable choice than CLL
patients as they are less familiar with the consequences of
not testing, this was judged to be sufficiently low that the
additional complexity outweighed the information that was
likely to be provided on uptake.
Respondents were asked to complete 16 choice sets.
This decision was informed by studies which suggest that,
below 17 choice sets, the number of choice sets does not
impact on response rates [32, 33]. The two alternatives in
each set were unlabelled to ensure that respondents based
Patients’ Preferences for Genomic Testing in CLL 527
decisions on attribute levels, not test names. At no point
were tests called ‘genetic’ or ‘genomic’; they were only
defined by attributes and levels.
A second pilot was then undertaken to generate priors to
inform the main design. A fractional factorial design was
produced using Ngene (ChoiceMetrics (2012) Ngene 1.1.1
User Manual & Reference Guide, Australia). Twelve CLL
patients at OUH completed the pilot. Multinomial logit
(MNL) regression was used to analyse the choice data in
Stata (StataCorp. 2011. Stata Statistical Software: Release
12. College Station, TX, USA: StataCorp LP). These priors
were incorporated into the final experimental design. This
design used a model-averaging approach which allowed us
to estimate a basic MNL model and then relax the
assumptions underlying this model to account for prefer-
ence heterogeneity using more general models (e.g. mixed
logit) [34]. Full details of the experimental design are
provided in Supplementary Materials–Part One: Additional
Information S2.
2.4 Constructing the Survey
The final survey comprised four sections and is provided in
Supplementary Materials–Part Two. Section one provided
respondents with background information on genetic and
genomic testing and described the attributes and levels. In
section two, respondents ranked attributes in order of
preference. Section three contained the DCE task, preceded
by a ‘rationality check’ choice in which Test A contained
the worst levels for each attribute and Test B contained the
best. Section four collected information on respondent
characteristics and clinical details. Respondents were also
asked for their opinions on genetic testing, to report their
current health status using the EuroQOL five dimensions
survey instrument, and to rate the difficulty of the survey.
2.5 Administering the Survey
The survey was administered in two forms. Patients at
OUH (n = 140) were asked to complete a paper survey
when they attended an outpatient appointment. CLLSA
patient members received either paper (n = 148) or elec-
tronic (n = 834) versions of the survey, depending on their
preferred means of contact. All patients wishing to return a
paper version of the survey received a prepaid envelope.
All patients received two reminders. Data collection took
place from July to October 2013. Ethical approval was
sought from the UK National Research Ethics Service and
the OUH NHS Foundation Trust R&D office. Both bodies
stated that ethical approval was not required.
Table 1 Discrete choice experiment attributes and levels
Attribute Level 1 Level 2 Level 3 Level 4 Expected impact




Time to receive the test
result [TIME]
5 days 8 days 11 days 14 days Negative
Cost of the test [COST] £130 £260 £400 £600 Negative
Ability of the test to
predict who will not
respond to the usual
chemotherapy
treatment [EFFECT]
Test identifies 30 out
of every 100
patients who will
not respond to usual
treatment
Test identifies 50 out
of every 100
patients who will
not respond to usual
treatment
Test identifies 70 out
of every 100
patients who will
not respond to usual
treatment
Test identifies 90 out
of every 100
patients who will
not respond to usual
treatment
Positive
Test reliability [REL] 2 out of every 100
tests provide an
incorrect result
4 out of every 100
tests provide an
incorrect result
6 out of every 100
tests provide an
incorrect result




Length of time clinicians
spend describing the
test to youa
5 min [INFO0] 10 min [INFO1] 15 min [INFO2] 20 min [base level] Positiveb
Type of clinician who












b Coded as categorical variable, but as levels were ordered by increasing time, a positive impact was predicted
c The levels for this attribute were deliberately ordered so that perceived knowledge about CLL increased from general practitioner to specialist
nurse to junior hospital doctor to consultant hospital doctor. This may not necessarily translate into a positive increasing effect on utility, as other
factors may also be important to patients
528 J. Buchanan et al.
2.6 Data Analysis
Data analysis was undertaken using Stata. In Model A, the
choice data was modelled using MNL regression, testing
main effects and differences by study design (including
sample population and completion method). This initial
model assumes that preferences are homogenous across
individuals. Model B tested the significance of attribute
interactions, and considered interactions between attributes
and respondent characteristics (gender, age, occupation,
children, income, time since CLL diagnosis, experience of
chemotherapy treatment and genetic testing, whether the
respondent had favourable opinions about genetic testing,
and health status). Finally, we accounted for the limitations
of MNL regression [31] by fitting alternative models (in-
cluding mixed logit and latent class models), which
allowed for preference heterogeneity. Different specifica-
tions were compared using the Akaike, Bayesian and
Consistent information criterion to identify the most
appropriate specifications.
For all models the marginal rate of substitution (the ratio
between cost and the other attributes) was calculated,
willingness-to-pay (WTP) for testing was estimated, and
ratios between attributes were calculated to understand
how much of one attribute respondents were willing to give
up to get more of a second attribute. We also calculated the
utility associated with genetic and genomic testing in this
context. To test the robustness of our results, models were
estimated without patients who failed the rationality check
and choices were evaluated separately for patients who
stated that the survey was difficult. The presence of dom-
inant preferences was explored by examining if respon-
dents always chose the test with the best level for a specific
attribute [35]. Again, models were run with and without
these patients. Finally, the proportion of correctly predicted
choices was estimated by calculating the utility associated
with each choice alternative, identifying the choice alter-
native with the highest utility, then calculating how fre-
quently this alternative was chosen by respondents.
3 Results
Eighty paper surveys [response rate (RR): 54 %] and 70
electronic surveys (RR: 8 %; overall RR: 15 %) were
received from CLLSA members. Of 140 patients asked to
complete a survey at OUH, 101 were recruited (39 already
participated in study/unwilling), with 69 paper surveys
returned (RR: 68 %). The overall response rate for paper
surveys was 60 %. 219 CLL patients completed a DCE in
total (RR: 20 %).
The age, gender distribution and employment status of
respondents were typical of CLL patients (Table 2) [24].
On average, respondents were diagnosed with CLL 6 years
before completing the survey, with half undergoing at least
one course of chemotherapy. Of these, 44 % had at least
one inpatient stay due to chemotherapy treatment, with
12 % currently undergoing chemotherapy. One in five
reported undergoing genetic testing, with 96 % in favour of
pre-treatment genetic or genomic tests (Supplementary
Materials–Part One: Table S3). The current quality of life
of respondents matched UK population norms [36, 37].
Table S4 (Supplementary Materials–Part One) presents
additional demographic information for DCE respondents,
broken down by type of respondent (OUH or CLLSA) and
method of completion (paper or electronic). Respondent
demographics were relatively consistent across these cat-
egories. In terms of type of respondent, more OUH patients
had undergone chemotherapy at least once (62 vs. 38 %),
whereas more CLLSA patients had undergone genetic
testing (26 vs. 7 %). In terms of method of completion,
respondents who completed electronic surveys were more
likely to be male (66 vs. 48 %), had left full-time education
at an older age (20.4 vs. 17.9 years), were less likely to
have had at least one course of chemotherapy (32 vs. 52 %)
but were more likely to have had an inpatient stay fol-
lowing chemotherapy treatment (59 vs. 39 %).
Most respondents (97 %) passed the rationality check,
with 9 % rating the DCE as difficult. Prior to undertaking
the DCE, the most important attribute to respondents was
EFFECT and the least important was COST (Supplemen-
tary Materials–Part One: Table S5). Almost all of the
patients who chose to participate in the DCE survey
completed all 16 choice questions, with only 0.8 % of
choice questions not answered. Missing questions were
mostly consecutive (i.e. respondents likely turned over two
pages at once), so were assumed to be missing at random.
Ninety-six respondents (44 %) made dominant choices,
although 88 (92 %) were dominant for EFFECT, which
exhibited overlap in 25 % of choice sets (hence it was
easier to be dominant on this attribute).
3.1 Model A
Table 3 presents the results for Model A, which tested
main effects and differences by study design. Initial anal-
yses considered the impact on model performance of
excluding respondents who failed the rationality check,
made dominant choices, described the DCE as difficult or
missed choice tasks. The only exclusion that increased
pseudo-R2, changed at least one coefficient from insignif-
icant to significant and retained sufficient choice data was
excluding respondents who described the DCE as difficult
(n = 19). These patients also missed out a greater pro-
portion of the choice questions (2.0 %) compared to those
who said the DCE was not difficult (0.7 %). These
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patients—who were older (71.7 years) and left full-time
education earlier (17.7 years) than respondents who did not
describe the DCE as difficult—were therefore excluded
from the analysis.
The TIME, COST, EFFECT (test effectiveness) and
REL (test reliability) coefficients in Model A all had the
expected sign: respondents prefer tests that are more
effective, more reliable, cheaper and return results quickly.
The signs for the INFO coefficients indicated that only a
15-min appointment with a clinician has a positive impact
on utility. The signs for the WHO coefficients indicated a
utility gain only when results are explained by specialist
nurses or consultant hospital doctors. Figures 1 and 2
(Supplementary Materials–Part One: Figures S6) illustrate
the non-linearity of the coefficients for the levels of the
INFO and WHO attributes. Improvements in test effec-
tiveness are valued, with patients willing to pay £24 for a
1 % increase in the proportion of chemotherapy non-re-
sponders identified. However, process attributes are also
valued: patients are willing to pay £27 to reduce time to
receive test results by 1 day. The coefficient ratios indi-
cated that respondents would be willing to wait an extra
29 days for test results if an additional one-third of
chemotherapy non-responders could be identified. Alter-
natively, respondents would tolerate a genomic test being
wrong 8 % of the time to receive this information. Finally,
receiving results from a consultant hospital doctor instead
of a general practitioner is equivalent to a 15 % increase in
test effectiveness.
When Model A was estimated separately for different
survey formats, pseudo-R2 was higher (0.5362 vs. 0.3335)
for the model containing DCEs completed electronically
(although the signs and significance of most coefficients
did not change). WTP for a 1 % increase in test
Table 2 Discrete choice experiment respondent characteristics
Variable Value N
Male 117 (53 %) 219
Mean age, years (SD) 65.7 (10.2) 205
Employment status 219
Employed 67 (31 %)
Retired 138 (63 %)
Other 14 (6 %)
Mean age on leaving full-time education in years (SD) 18.7 (4.5) 205
Mean household income, £ 30,646 201
Mean number of people per household (SD) 2.0 (0.9) 212
Mean number of children (SD) 219
At home 0.4 (0.8)
Away from home 1.7 (1.3)
Mean travel time to hospital, min 35.5 217
Mode of transport used to reach hospital 215
Hospital arranged 3 (1 %)
Public transport 34 (16 %)
Private transport 178 (83 %)
Mean time since diagnosis, years (SD) 6.0 (4.5) 215
Number of respondents who have undergone chemotherapy at least once 98 (45 %) 216
Average number of courses of chemotherapy in these respondents (SD) 1.3 (0.8) 93
Number of respondents who have had an inpatient stay after chemotherapy treatment 42 (44 %) 96
Number of respondents undergoing chemotherapy currently 11 (12 %) 94
Number of respondents who had undergone genetic testing previously 44 (20 %) 216
Mean EQ-5D score (SD)a 0.823 (0.225) 217
Mean EQ-VAS score (SD)a 74.2 (17) 210
SD standard deviation
a The EuroQOL five dimensions (EQ-5D) survey instrument is designed for self-completion by respondents and collects information on health-
related quality of life in two ways. Firstly, respondents rate their health in five dimensions (Mobility, Self-care, Usual activity, Pain/discomfort,
Anxiety/Depression) in terms of three levels (the EQ-5D score). Secondly, respondents record an overall assessment of their health on a visual
analogue scale which runs from 0 to 100 (the EQ-VAS score)
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effectiveness was higher when the DCE was completed
electronically (£24.33 vs. £20.92), as was WTP for a 1 %
improvement in test reliability (£93.33 vs. £82.99). When
Model A was estimated separately by sample population,
pseudo-R2 was higher for the model for UK CLLSA
respondents (0.4510 vs. 0.2735), although the signs and
significance of most coefficients again remained the same.
WTP for a 1 % increase in test effectiveness was higher for
CLLSA respondents (£32.21 vs. £14.07), while WTP for a
1 % improvement in test reliability was higher for OUH
respondents (£121.06 vs. £58.53).
3.2 Model B
Model B evaluated interactions. Neither of the planned
interactions (COST 9 EFFECT, COST 9 REL) were
significant, so were excluded from the final specification.
However, when significant interactions between attributes
and respondent characteristics were added (Table 3),
pseudo-R2 increased and the significance of INFO0
improved. Notable interactions included MALE 9 INFO0
(men have a stronger preference for shorter appointments),
MALE 9 WHO0 (men have a stronger preference for
receiving results from general practitioners), and INCO-
ME 9 REL (higher income patients have a weaker pref-
erence for more reliable tests).
3.3 Alternative Model Specifications
Supplementary Materials–Part One: Table S7 presents a
comparison of alternative model specifications. These
results confirm that Model B provides a better fit than
Model A. However, alternative specifications provide a
better fit than MNL for both models. For Model A the most
appropriate specification is either a mixed logit or latent
class approach. As limited information is available to
characterise the latent classes in this main effects model,
the mixed logit approach is taken forward. Coefficients and
WTP values for this model (hereafter Model C) are pre-
sented in Table 3. The significance of most coefficients
remains the same as in Model A, although three are no
longer significant: INFO0, INFO1 and INFO2.
Notable changes in WTP include EFFECT (increases from
£23.79 to £53.79) and REL (decreases from -£93.38 to
-£155.73). Overall, Model C correctly predicted 81 % of
respondent choices.
For Model B a latent class model is the most appropriate
specification. Given that a series of assumptions are
required concerning respondent characteristics in order to
use the results of this model to calculate WTP, these results
are presented separately (Supplementary Materials–Part
One: Table S8).
3.4 Utility Calculations for Genetic and Genomic
Testing
The utility calculations for genetic and genomic testing are
presented in Supplementary Materials–Part One: Addi-
tional Information S9. In both Model A and Model C,
genomic testing is associated with higher utility: the utility
gain associated with improvements in test effectiveness
and reliability surpasses the utility loss associated with the
higher cost of genomic testing.
4 Discussion
This paper presents the results of a DCE survey which
evaluated the preferences of UK CLL patients for pre-
treatment genetic and genomic testing. This survey
revealed that patients prefer tests that are more effective,
more reliable, cheaper and which return results quickly.
Patients prefer to receive these test results in a 15-min
appointment with a clinician who is perceived to be a CLL
expert. Both clinical and process-related attributes are
important to patients, with test effectiveness and speed of
result ranked highly. Patient characteristics may modify
these findings, with male patients (who account for two-
thirds of CLL incidence and have worse outcomes [38])
having a stronger preference than women for shorter
appointments with general practitioners (rather than with
hospital-based clinicians). This supports the suggestion that
health-seeking behaviour differs between men and women
[39, 40].
Overall, respondents expressed a preference for combi-
nations of attributes and attribute levels that more closely
reflect genomic testing than genetic testing. Indeed,
respondents were willing to make notable trade-offs for the
extra information provided by genomic testing (including
waiting a month longer for results if genomic testing can
identify an additional one-third of chemotherapy non-re-
sponders). Furthermore, when the likely specifications of
genetic and genomic testing were valued using the coeffi-
cient estimates generated in the choice models, genomic
testing was always associated with higher utility than
genetic testing.
These findings match those of other DCEs that have
evaluated genetic and genomic tests. Regier et al. evaluated
the use of genomic testing to identify the genetic causes of
developmental disability, reporting that both the diagnostic
rate and waiting time for test results were important to
families [41, 42]. Herbild et al. evaluated WTP for phar-
macogenetic testing in the treatment of depression and
found that respondents placed a high value on how the
intervention was delivered [43]. Finally, Najafzadeh et al.
532 J. Buchanan et al.
measured the preferences of patients and the general public
for genomic testing to determine drug response, finding
that both clinical (e.g. test effectiveness) and process-re-
lated attributes (e.g. genetic test procedure) are important
to respondents [44].
Our study has several limitations. First, a broad cross-
section of patients was targeted by using two sampling
populations. However, some patients may be under-repre-
sented and our sample may therefore be characterised by
selective non-response. The most severely ill patients may
have been unable to participate, while the healthiest OUH
patients (who only have annual check-ups) may not have
been sampled. Furthermore, CLLSA members differ from
non-members. However, given that respondent character-
istics were typical of CLL patients [24], these factors are
unlikely to have affected the DCE results.
Second, the DCE response rate was low, particularly for
CLLSA members who completed electronic surveys. DCE
response rates have been decreasing over time [45] and low
response rates are no longer unusual, particularly in elderly
populations and for electronic DCE surveys [46]. Further-
more, evidence suggests that response rates are lower when
more than four attributes are included in a DCE, and when
there is no opt-out [45]. However, most published DCEs
include between 100 and 300 respondents and our sample
size of 219 respondents does fall within this range [47, 48].
It has been noted previously that response rates are posi-
tively related to the perceived benefits of completing a
DCE survey [45], hence it is possible that the low response
rate to our survey may have impacted on the DCE results.
Specifically, if those who completed the survey were pri-
marily patients who were more aware of the benefits of
testing (e.g. patients who had previously undergone
chemotherapy and were thus familiar with the conse-
quences of treatment) this might have biased WTP esti-
mates upwards. However, as 55 % of respondents had not
undergone chemotherapy and respondent quality-of-life
matched population norms, we do not believe that the low
response rate impacted on our results in this manner.
Third, an opt-out design was tested in a pilot which used
a convenience sample of non-CLL patients and which
found that the opt-out option was rarely selected. Ideally,
this pilot would have used CLL patients, but the small pool
of OUH patients precluded this approach. As CLL patients
are rarely able to choose ‘no test’ in the UK and general
population respondents may consider an opt-out to be a
more viable choice than CLL patients, it is likely that a
pilot of the opt-out design in CLL patients would have seen
even fewer respondents selecting the opt-out option, pro-
viding further justification for this design decision.
Fourth, the TIME, COST, EFFECT and REL attributes
were assumed to be linear and coded as continuous attri-
butes to permit the use of the DCE results to characterise
genomic testing practice (whose attributes were unknown
at that time) in future cost-benefit analyses. It is, however,
possible that the relationship between these attributes and
utility is not linear, hence this is a potential weakness of
our study.
Finally, 19 respondents described the DCE as difficult
and were excluded from the analysis, which improved
model fit. These respondents were excluded because we
could not be sure that they understood the choice questions.
These patients also missed out a greater proportion of the
choice questions compared to those who said the DCE was
not difficult, hence their responses provided limited addi-
tional information on trade-offs between test attributes.
This decision was considered carefully as it has been
suggested that the removal of such respondents is inap-
propriate [32]. As few respondents were affected, this
decision is unlikely to have affected the main conclusions
of this study. Furthermore, by removing respondents who
may not have understood the choice questions, these con-
clusions may also be more robust.
The results of this study have implications for decision-
making in both CLL and genomics more generally. CLL
patients clearly value the additional clinical information
that could be provided by genomic tests; however, several
process-related attributes are also important to them. This
suggests that for genomic testing to be implemented suc-
cessfully, commissioners will need to ensure that test
results are delivered by approved CLL clinicians in an
appropriate environment. Furthermore, implementation
may need to be tailored to the preferences of specific
patient subgroups, with gender, income and previous
treatment experience all influencing preferences.
However, these results alone are not sufficient to make
a case for introducing genomic testing in CLL. Future
work should combine these results with information on
test costs in an economic evaluation to establish whether
genomic testing provides value for money in this context,
i.e. do the benefits surpass the costs. One way in which
this could be partially achieved is to use this behavioural
information as an input into a cost-effectiveness or cost-
utility analysis (e.g. accounting for potential deviations
from a 100 % participation rate). However, given the
importance that CLL patients attached to process-related
outcomes, the most appropriate form of economic evalu-
ation could instead be a cost-benefit analysis (CBA), in
which health outcomes are expressed in monetary terms,
informed by the WTP estimates generated by this DCE.
However, CBAs are rarely undertaken at present as they
are not valued by HTA agencies such as the National
Institute for Health and Care Excellence in the UK [49].
Future work which demonstrates that CBAs are a valid
approach in this context would make a notable contribu-
tion to this area.
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More generally, these findings suggest that studies
which use narrowly-defined outcome measures such as the
QALY may not capture all the benefits of genomic testing
that are important to patients. One possible consequence of
ignoring process-related outcomes is that commissioners
may make sub-optimal decisions concerning the provision
of genomic testing services. Additional work to evaluate all
the clinical and process-related outcomes of genomic
testing in a variety of clinical contexts may therefore
facilitate the more efficient allocation of limited healthcare
resources in the future.
The key finding in this study is that both clinical and
process-related outcomes are valued by patients when
considering the use of genomic testing to guide CLL
treatment decisions. This finding is potentially generalis-
able to other clinical areas in which genomic tests with
similar characteristics (e.g. cost, time to receive results)
can guide treatment. This includes other cancers such as
colorectal cancer, in which genomic testing can guide the
use of expensive targeted therapies [50], and chronic dis-
eases such as cystic fibrosis, where genomic testing can
inform the use of treatments which help patients to live a
more symptom-free life [51]. Policy-makers should be
aware that these genomic tests will likely need to demon-
strate both effectiveness and reliability, deliver results in a
timely manner, and be fully explained to patients by
qualified clinicians in order for patients to participate fully
in such testing programmes. If this is not achieved, the full
health benefits of genomic testing are unlikely to be
realised.
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